DxS, a personalised medicine company, has signed an agreement with Amgen to provide a K-Ras companion diagnostic for Vectibix (panitumumab) in the US.
DxS and Amgen will work together in the US to facilitate the use of Vectibix in metastatic colorectal cancer patients with wild-type K-Ras status.
The companies hope DxS's Therascreen: K-Ras Mutation Kit will become a companion diagnostic for use with Vectibix if approved by the FDA.
This agreement between Amgen and DxS follows a collaboration entered into by the parties last year with respect to the Therascreen: K-Ras Mutation Kit in Europe.
